Semorinemab scFv-Transferrin Fusion for Barrier-Penetrating Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their therapeutic efficacy and application.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to bind with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis, with enzymatically sensitive linkers for controlled release within target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a whole antibody is used for therapeutic delivery, then effector functions and half-life are improved, but penetration across biological barriers and cellular uptake are reduced
Solution Approach 1:
The antibody is segmented into a single-chain variable fragment (scFv) that retains antigen-binding capability while eliminating the Fc region. This segmentation reduces molecular weight from ~150 kDa to ~25-30 kDa, enabling better penetration across biological barriers while the scFv can be separately conjugated to transferrin for enhanced cellular uptake
Solution Approach 2:
The scFv is merged with transferrin protein to create a fusion construct that combines the antigen-specific binding capability of the antibody with the transcytosis-promoting properties of transferrin. This merging enables the therapeutic agent to both bind its target and efficiently cross biological barriers through the transferrin receptor pathway
2Length of moving object
If antibody size is reduced to scFv for better barrier penetration, then transcytosis capability is improved, but effector functions and half-life are lost
Solution Approach 1:
Transferrin acts as an intermediary that mediates cellular uptake and transcytosis for the scFv. The transferrin-conjugated scFv utilizes the transferrin receptor-mediated endocytosis pathway to efficiently cross the blood-brain barrier and enter cells, compensating for the loss of Fc-mediated effector functions while maintaining or enhancing delivery efficacy
Solution Approach 2:
The molecular weight parameter is changed by removing the Fc region to create scFv, enabling better barrier penetration. The transferrin conjugation then modifies the pharmacokinetic parameters, providing extended circulation half-life through reticuloendothelial system uptake mechanisms while maintaining the small size advantage for barrier crossing
3Object-generated harmful factors
If Fc region is retained for immune responses, then ADCC and ADCP mechanisms are activated, but transcytosis promotion and cellular entry are reduced
Solution Approach 1:
The Fc region is extracted from the antibody structure, removing the capability for Fc receptor-mediated immune effector functions (ADCC, ADCP) while retaining the antigen-binding scFv portion. The extracted scFv is then conjugated to transferrin to provide alternative delivery mechanisms that promote transcytosis and cellular entry without relying on Fc-mediated immunity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced delivery and efficacy by improving penetration across biological barriers, reducing off-target effects, and ensuring targeted release of therapeutic agents within specific cells.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis
Implementation Method 2
with enzymatically sensitive linkers for controlled release within target cells
Data Source
AI summary
The efficacy and indication of semorinemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.